Biotech patent playbook expands to outpace global fast followers
Biotech firms facing faster, cheaper Chinese trials must broaden patent coverage beyond their core assets and carefully manage public messaging to avoid signaling competitors. Experts advise filing on related pathways and variations, and even subtle misdirection strategies—like cheap early patents for assets they plan to abandon—to throw off fast followers, while maintaining broad, foundational claims to protect technology.